Potassium Bicarbonate + Sodium Alginate
This should be prescribed with caution in patients with renal impairment and congestive cardiac failure.
Heartburn, Indigestion, Gastro-oesophageal reflux, Acid regurgitation, Reflux esophagitis
Sodium alginate and potassium bicarbonate is contraindicated in patients with known hypersensitivity to these.
N/A
Nausea, constipation, diarrhea or headache.
Potassium depletion occurs when rate of loss through renal excretion and/or GI tract exceeds intake. Supplementation with potassium-containing products may alleviate depletion. Potassium plays essential role in the conduction of nerve impulses in the heart, brain, and skeletal muscle; plays a role in contraction of cardiac, skeletal, and smooth muscles. Alginic acid is used in combination with an antacid or histamine H2-antagonist in the management of gastro-esophageal reflux disease. It reacts with gastric acid to form a viscous gel which acts as a mechanical barrier to reduce reflux.
N/A
N/A
Tablet Adult: 1-2 tablets daily 4 times, after meals & before bedtime. Suspension Adult: 5-10 ml Daily 4 times, after meals & before bedtime.
Tablet Child over 12 years: 1-2 tablets daily 4 times, after meals & before bedtime. Child 6-12 years: 1 tablet Daily 4 times, after meals & before bedtime. Suspension Child over 12 years: 5-10 ml Daily 4 times, after meals & before bedtime. Child 2-12 years: 2.5-5 ml Daily 4 times, after meals & before bedtime. It is not recommended for children under 2 years of age.
N/A
N/A
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.